Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2007

View Archived Issues

Outcome of Erbitux phase III study in first-line treatment of advanced lung cancer

Ariad and Merck & Co. enter global collaboration to jointly develop and market AP-23573

New therapeutic agents for psychiatric disorders reported in recent patents

Recent patents disclose novel treatments for inflammatory disorders

Patient enrollment begins for phase II IMC-A12 study in advanced colorectal cancer

Encysive Pharmaceuticals provides update on Thelin NDA

Tikvah Therapeutics completes private financing

LAB International changes name to Akela Pharma

Enrollment of phase IIa trial of MEM-3454 for AD completed

Enrollment of Dynavax's pivotal phase III trial of HBV vaccine completed

FDA accepts Collegium's IND for abuse deterrent, sustained release opioid

Jerini Ophthalmic's IND for JSM-6427 for AMD accepted by FDA

Valopicitabine program placed on hold in U.S.

Recent patents impart novel analgesic agents

New Alzheimer's disease remedy disclosed in recent Roche patent

ERCC1 mRNA measurement used to assign non-small cell lung cancer treatment

Clinical centers now being recruited for DIMOND study

RON receptor tyrosine kinase a potential pancreatic cancer target

Renal impairment implicated in progression to prediabetes

Selenium supplementation does not prevent type 2 diabetes

Diabetes incidence reduced in rheumatoid arthritis patients taking hydroxychloroquine

Bionomics advances development of potassium channel Kv1.3 blockers

Studies characterize direct thrombin inhibitor AZD-0837

Colostrinin launched in Australasia

Ceftobiprole filed in Canada for cSSSI

Neupro launched in U.S.

Testosterone MD-Lotion elevates testosterone levels into normal healthy range

Iclaprim achieves primary efficacy endpoint in phase III cSSSI trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...